Patent US5236908A successfully refreshed from Google Patents.
US5236908A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of treating injury to the central nervous system
Assignee: Sicor Inc
•
Filing: 1991-06-07
•
Granted: 1993-08-17
•
Expires: 2011-06-07
Abstract
Abstract The invention provides methods for preventing neural tissue damage caused by injury to the central nervous system (CNS) by the administration of a therapeutically effective amount of an adenosinergic agent. One aspect of the invention is directed toward continuous administration of a therapeutically effective amount of an adenosinergic agent for a period of time sufficient to prevent neural tissue damage. In another aspect of the present invention, the adenosinergic agents may be administered on several occasions during the prolonged period of treatment, so long as the doses of adenosinergic agents are spaced in time so that a therapeutically effective concentration of adenosinergic agent is maintained for a period of time sufficient to prevent neural tissue damage.
Inventors
- 👤 Harry E. Gruber
- 👤 Leonard P. Miller
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 09:27
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61P; A61P25/00
Claims Analysis
Total Claims: 35
Claim 1
Independent Claim
45 words
A method of preventing neural tissue damage caused by injury to the central nervous system of a warm-blooded animal comprising continuously administering to said warm-blooded animal a therapeutically effective amount of an adenosine agonist for a period of time sufficient to prevent neural tissue damage.
Claim 2
Independent Claim
45 words
A method of preventing neural tissue damage caused by injury to the central nervous system of a warm-blooded animal comprising continuously administering to said warm-blooded animal a therapeutically effective amount of an adenosine agonist for a period of time sufficient to prevent neural tissue damage.
Claim 3
Independent Claim
61 words
A method of preventing neural tissue damage caused by injury to the central nervous system of a warm-blooded animal comprising administering to said warm-blooded animal a plurality of doses of an adenosine agonist, said doses being spaced in time to maintain a therapeutically effective concentration in said central nervous system for a period of time sufficient to prevent neural tissue damage.
Claim 4
Independent Claim
61 words
A method of preventing neural tissue damage caused by injury to the central nervous system of a warm-blooded animal comprising administering to said warm-blooded animal a plurality of doses of an adenosine agonist, said doses being spaced in time to maintain a therapeutically effective concentration in said central nervous system for a period of time sufficient to prevent neural tissue damage.
Claim 5
Dependent Claim
23 words
A method according to claim 1 or 2 wherein said time period for administration of said adenosine agonist is longer than 4 hours.
Claim 6
Dependent Claim
24 words
A method according to claim 1 or 2 wherein said period of time for administration of said adenosine agonist is longer than 8 hours.
Claim 7
Dependent Claim
24 words
A method according to claim 1 or 2 wherein said period of time for administration of said adenosine agonist is longer than 12 hours.
Claim 8
Dependent Claim
24 words
A method according to claim 1 or 2 wherein said period of time for administration of said adenosine agonist is longer than 24 hours.
Claim 9
Dependent Claim
24 words
A method according to claim 1 or 2 wherein said period of time for administration of said adenosine agonist is longer than 48 hours.
Claim 10
Dependent Claim
52 words
A method according to claim 1 or 2 wherein said therapeutically effective amount of adenosine agonist is the amount of said adenosine agonist which results in a concentration of said adenosinergic agent in the central nervous system of comparable potency to CHA at concentrations from 10 -9 M to 10 -6 M.
Claim 11
Dependent Claim
52 words
A method according to claim 1 or 2 wherein said therapeutically effective amount of adenosinergic agent is the amount of said adenosine agonist which results in a concentration of said adenosine agonist in the central nervous system of comparable potency to CHA at concentrations from 10 -8 M to 10 -7 M.
Claim 12
Dependent Claim
26 words
A method according to claim 1 or 2 wherein said adenosine agonist activates A 1 adenosine receptors for a period of time longer than 4 hours.
Claim 13
Dependent Claim
26 words
A method according to claim 10 wherein said adenosinergic agent has a ratio of affinity for A 1 receptors: A 2 receptors at least about 400:1.
Claim 14
Dependent Claim
27 words
A method according to claim 10 wherein said adenosinergic agent has a ratio of affinity for A 1 receptors: A 2 receptors of at least about 800:1.
Claim 15
Dependent Claim
21 words
A method according to claim 10 wherein said effective amount of said adenosine agonist is from 0.01 mg/kg/day to 10 mg/kg/day.
Claim 16
Dependent Claim
23 words
A method according to claim 1 or 2 wherein said effective amount of adenosine agonist is from 0.01 mg/kg/day to about 500 mg/kg/day.
Claim 17
Dependent Claim
24 words
A method according to claim 1 or 2 wherein said effective amount of adenosine agonist is from about 1 mg/kg/day to about 200 mg/kg/day.
Claim 18
Dependent Claim
40 words
A method according to claim 1 or 2 wherein said adenosine agonist crosses the blood brain barrier sufficiently to achieve levels in the cerebrospinal fluid and/or brain tissue which are at least 10% of plasma levels of said adenosine agonist.
Claim 19
Dependent Claim
15 words
A method according to claim 1 or 2 wherein said adenosine agonist is administered intrathecally.
Claim 20
Dependent Claim
15 words
A method according to claim 1 or 2 wherein said adenosine agonist is administered intravenously.
Claim 21
Dependent Claim
15 words
A method according to claim 1 or 2 wherein said adenosine agonist is administered orally.
Claim 22
Dependent Claim
15 words
A method according to claim 1 or 2 wherein said adenosine agonist is administered prophylactically.
Claim 23
Dependent Claim
25 words
A method according to claim 1 or 2 wherein said administration of said adenosine agonist is begun after said injury to the central nervous system.
Claim 24
Dependent Claim
18 words
A method according to claim 1 or 2 wherein said injury to the central nervous system is stroke.
Claim 25
Dependent Claim
11 words
A method according to claim 22 wherein said stroke is focal.
Claim 26
Dependent Claim
19 words
A method according to claim 1 or 2 wherein said injury to the central nervous system is brain trauma.
Claim 27
Dependent Claim
19 words
A method according to claim 1 or 2 wherein said injury to the central nervous system occurs during surgery.
Claim 28
Dependent Claim
12 words
A method according to claim 25 wherein said surgery is carotid endarterectomy.
Claim 29
Dependent Claim
14 words
A method according to claim 25 wherein said surgery is coronary artery bypass graft.
Claim 30
Dependent Claim
33 words
A method according to claim 25 wherein said administration of adenosine agonist is begun prior to surgery and continues during the surgery and for a period of longer than 4 hours after surgery.
Claim 31
Dependent Claim
18 words
A method according to claim 1 or 2 wherein said injury to the central nervous system is ischemia.
Claim 32
Independent Claim
18 words
A method of attenuating-glycine release in a warm-blooded animal comprising administering an adenosine agonist to said warm-blooded animal.
Claim 33
Independent Claim
18 words
A method of attenuating-glycine release in a warm-blooded animal comprising administering an adenosine agonist to said warm-blooded animal.
Claim 34
Independent Claim
23 words
A method of alternating glycine and excitatory amino acid release in a warm-blooded animal comprising administering to said warm-blooded animal an adenosine agonist.
Claim 35
Independent Claim
23 words
A method of alternating glycine and excitatory amino acid release in a warm-blooded animal comprising administering to said warm-blooded animal an adenosine agonist.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-16 | 1997-02-15 | 1997-08-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-16 | 2001-02-15 | 2001-08-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-16 | 2005-02-15 | 2005-08-17 | $7700.00 | Window Closed / Lapsed |